Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure

Summary

Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) have shown promise for increasing use of GDMT. However, these tools have not been broadly implemented within large health systems. The goal of this study is to see if using these tools broadly within cardiology clinics will increase the use of GDMT. This study is important because it could help improve the use of GDMT, which may lead to improved patient care and outcomes.

Eligibility

Inclusion Criteria:

* Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months
* Diagnosis of heart failure

Exclusion Criteria:

* Heart failure (HF) etiology for which GDMT is not indicated: including hypertrophic or restrictive cardiomyopathy (e.g. amyloid cardiomyopathy), constrictive pericarditis, or complex congenital heart disease
* End-stage HF requiring continuous inotrope infusion, heart transplant, or left ventricular assist device
* Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2
* Any conditions other than HF that are likely to alter the patient's status over 6 months, indicated by active hospice status

Conditions2

Locations4 sites

Browse More Trials